Control (non-targeting) and
tgs1 morpholino oligonucleotides (MOs) were purchased from (GeneTools, LLC) using the
tgs1 XM_003197865.5 sequence as reference. MO sequences are reported in
Supplementary Table S11. For TGS1 mRNA injection, human
TGS1 cDNA (NM_001317902) was cloned into an N-terminal flag-pCS2 + mRNA expression vector.
In vitro transcription of 5′-capped mRNAs was performed using the
mMACHINE SP6 Transcription Kit (Ambion) following the manufacturer's protocol and as previously described in (33 (
link),34 (
link)). Embryos from TL/EK wild-type crossings were used to visualize the CaP-MN phenotype. Embryos were injected with the respective dose of MOs or mRNA in an aqueous solution containing 0.05%
PhenolRed and 0.05%
Rhodamine-Dextran (Sigma-Aldrich). At 6–7 h after injection, embryos were sorted according to homogeneity of the rhodamine fluorescence signal.
Chen L., Roake C.M., Maccallini P., Bavasso F., Dehghannasiri R., Santonicola P., Mendoza-Ferreira N., Scatolini L., Rizzuti L., Esposito A., Gallotta I., Francia S., Cacchione S., Galati A., Palumbo V., Kobin M.A., Tartaglia G.G., Colantoni A., Proietti G., Wu Y., Hammerschmidt M., De Pittà C., Sales G., Salzman J., Pellizzoni L., Wirth B., Di Schiavi E., Gatti M., Artandi S.E, & Raffa G.D. (2022). TGS1 impacts snRNA 3′-end processing, ameliorates survival motor neuron-dependent neurological phenotypes in vivo and prevents neurodegeneration. Nucleic Acids Research, 50(21), 12400-12424.